A description of the invention will be available after the patent application is published. Nencki Institute is the co-applicant with Medical University of Warsaw, International Institute of Molecular and Cell Biology in Warsaw, and Children’s Memorial Health Institute in Warsaw. Medical University of Warsaw is the leader in patent protection and commercialization-related activities. For more…
Description of the invention will be available after the patent application is published.
Description of the invention will be available after the patent application is published.
Description of the invention will be available after the patent application is published.
Patent was granted in Poland and Nencki Institute is the sole applicant.
The subject of the present invention is a method for detecting active, remyelinating lesions in patients diagnosed with multiple sclerosis through the determination of changes in the levels of interleukin-33 in peripheral blood and cerebrospinal fluid, which constitutes a novel marker of endogenous repair processes facilitating the monitoring of the differentiation of oligodendrocyte precursor differentiation…
The present invention relates to methods for the identification of single nucleotide polymorphisms (SNP) in the GRHL1, GRHL2 and GRHL3 genes and the use of these polymorphisms as markers to identify patients at increased susceptibility to cancer of the kidneys.